# Sensei Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sensei-biotherapeutics

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.senseibio.com
- Total disclosed funding: $59M
- Latest round: Series B (Jan 11, 2021)
- Investors on record: 8

## About

Founded in 1999 and based in Maryland, US, Sensei Biotherapeutics, Inc. operates as a biotechnology company that discovers and develops medicines through a vaccine platform to train the immune system, react to specific antigens, and treat immuno-oncology patients. The company raised a total of USD 58.5 million in two funding rounds and, in November 2020, filed for an IPO (Initial Public Offering) prospectus.

The company's medical R&D team focuses on developing personalized immune therapy for various tumor types and infectious diseases through ImmunoPhage, a platform that engineers non-infectious lambda bacteriophage viruses to display target antigens on the capsid surface, as well as a library of pre-made, clinical-grade bacteriophage vaccines. The product pipeline includes SNS-301, SNS-401, and SNS-VISTA.

The company finances operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, distribution, and licensing arrangements.

The company plans to list on the Nasdaq global select market under the ticker symbol SNSE.

## Funding rounds

- Series B, Jan 11, 2021, $30M — Pura Vida Investments, Apeiron Investment Group, Future Ventures, Moore Strategic Ventures, Presight Capital, Catalio Capital Management, Cambrian Biopharma
- Series A, Oct 7, 2020, $29M — H&S Ventures, Future Ventures, Apeiron Investment Group, Presight Capital, Cambrian Biopharma

## Investors

- H&S Ventures — Series A
- Future Ventures — Series A, Series B
- Apeiron Investment Group (https://capitalatlas.ai/funds/apeiron-investment-group) — Series A, Series B
- Presight Capital — Series A, Series B
- Cambrian Biopharma (https://capitalatlas.ai/funds/cambrian-biopharma) — Series A, Series B
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series B
- Moore Strategic Ventures (https://capitalatlas.ai/funds/moore-strategic-ventures) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B